Citigroup’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-1,872
Closed -$148K 7764
2017
Q4
$148K Buy
+1,872
New +$139K ﹤0.01% 5302

Other funds holding MLNT

Citigroup's MLNT Position: Q4 2019 in Review

Citigroup sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 783 shares — an estimated $3K sold.

Citigroup first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $46K in Q3 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

  • Citigroup reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Citigroup sold 783 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3K.
  • Citigroup first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
  • Citigroup's Melinta Therapeutics, Inc. Common Stock position peaked at $46K in Q3 2018.
  • 37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.